Nimotuzumab
Product Specifications
UNSPSC Description
Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR with a KD of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC)[1][2].
Target Antigen
EGFR
Type
Inhibitory Antibodies
Related Pathways
JAK/STAT Signaling;Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/nimotuzumab.html
Purity
96.80
Solubility
H2O
Smiles
[Nimotuzumab]
References & Citations
[1]Zaima Mazorra, et al. Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients. Front Pharmacol. 2017 Jun 19;8:382.|[2]Melarkode S Ramakrishnan, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs. Jan-Feb 2009;1(1):41-8.
Shipping Conditions
Blue Ice
Storage Conditions
Store at 4°C for 2 years, do not freeze
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P9968/Nimotuzumab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P9968/Nimotuzumab-SDS-MedChemExpress.pdf
Clinical Information
Launched
CAS Number
780758-10-3
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
